Title
Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review
Date Issued
01 April 2018
Access level
open access
Resource Type
review
Author(s)
Universitat de Barcelona
Publisher(s)
W.B. Saunders Ltd
Abstract
Background: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined. Methods: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe. Results: The overall incidence rates for CAP was 68–7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16–3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%–78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination. Conclusions: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.
Start page
6
End page
13
Volume
137
Language
English
OCDE Knowledge area
Patología
Enfermedades infecciosas
Sistema respiratorio
Subjects
Scopus EID
2-s2.0-85042365671
PubMed ID
Source
Respiratory Medicine
ISSN of the container
09546111
Sponsor(s)
The authors would like to thank Pfizer's country Medical Affairs offices for providing translations of local publications on incidence and pneumococcal vaccination uptake data and Jose Morato Martinez (Pfizer International Operations, France) for coordinating the collation of this information. The authors take full responsibility for the content of this article and thank Neostar Communications Ltd., Oxford, UK (funded by Pfizer, Paris, France) for their assistance in preparing the manuscript, including preparing the first draft in close collaboration with the authors and the collation of author comments, and Tricia Newell, PhD, of Complete Healthcare Communications, LLC, West Chester, PA, USA (funded by Pfizer Inc) for preparing the final manuscript for submission. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Sources of information:
Directorio de Producción Científica
Scopus